IP Library Granted Patent US 7,418,290
Granted Patent B2
US 7,418,290 · App. 10/840,343 · Granted Aug 26, 2008

System and method of assessment of the efficacy of treatment of neurological disorders using the electroencephalogram

Assignee: Aspect Medical Systems, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,418,290
App. No.
10/840,343
Granted
Aug 26, 2008
Kind
B2
Abstract

Disclosed is a system and method of assessing the efficacy of treatment of neurological or psychological disorders. The preferred embodiment uses at least two surface electrodes to acquire EEG signals from the surface of a patient's body, a processor for computing from the EEG signals various features and indices that are representative of the patient's neurological or psychological state. Changes in these parameters may be used to assess the efficacy of treatment and to modify the treatment to optimize the resultant patient state.

Claims (62)

1. A system for assessing the efficacy of treatment of a neurological disorder comprising:

at least two electrodes for acquiring electrophysiological signals from the body suffering from a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

a processor for calculating from said electrophysiological signals at least one feature relating to the efficacy of said treatment without referencing said at least one feature to a normative data set, said at least one feature being a measure of a self-reported mood or anxiety score.

2. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said treatment is neurostimulation.

3. The system for assessing the efficacy of treatment of a neurological disorder of claim 2 wherein said neurostimulation is deep brain stimulation.

4. The system for assessing the efficacy of treatment of a neurological disorder of claim 2 wherein said neurostimulation is vagus nerve stimulation.

5. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said treatment is the administration of a pharmacological agent.

6. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said treatment is electroconvulsive therapy.

7. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said treatment is transcranial magnetic stimulation.

8. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said processor calculates at least two features and combines said at least two features into an index.

9. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said processor calculates at least one feature from a spectral array.

10. The system for assessing the efficacy of treatment of a neurological disorder of claim 8 wherein said processor calculates at least one feature from a power spectral array.

11. The system for assessing the efficacy of treatment of a neurological disorder of claim 8 wherein said processor calculates at least one feature from a bispectral array.

12. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said at least one feature is a time domain feature.

13. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said at least two electrodes are placed in a bilateral montage.

14. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said at least two electrodes are placed in an unilateral montage.

15. The system for assessing the efficacy of treatment of a neurological disorder of claim 1 wherein said feature is the interhemispheric difference in a metric calculated from each electrophysiological signal.

16. The system for assessing the efficacy of treatment of a neurological disorder of claim 15 wherein said metric is a spectral feature.

17. The system for assessing the efficacy of treatment of a neurological disorder of claim 15 wherein said metric is a time domain feature.

18. A system for assessing the efficacy of treatment of a neurological disorder comprising:

at least two electrodes for acquiring electrophysiological signals from a body suffering from a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

data acquisition circuitry for acquiring from said electrodes a first electrophysiological signal representing a baseline condition and a second electrophysiological signal representing a subsequent condition;

a processor for calculating from said electrophysiological signals received from the data acquisition circuitry:

(a) at least one feature relating to the patient state during the baseline condition, without referencing said at least one feature relating to the patient state during the baseline condition to a normative data set, said at least one feature relating to the patient state during the baseline condition being a measure of a self-reported mood or anxiety score;

(b) at least one feature relating to the patient state during the subsequent condition, without referencing said at least one feature relating to the patient state during the subsequent condition to a normative data set, said at least one feature relating to the patient state during the subsequent condition being a measure of a self-reported mood or anxiety score; and

(c) the difference between said features relating to the baseline and subsequent conditions, such that said difference relates to the efficacy of said treatment.

19. A system for optimizing the efficacy of treatment of a neurological disorder comprising:

at least two electrodes for acquiring electrophysiological signals from a body suffering from a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

processor for calculating from said electrophysiological signals at least one feature relating to the efficacy of said treatment without referencing said at least one feature to a normative data set, said feature being a measure of a self-reported mood or anxiety score;

data acquisition circuitry for acquiring said electrophysiological signals from said electrodes and converting said electrophysiological signals to a form usable by said processor;

a processor for varying the treatment parameters of a neurostimulator in order to maximize the calculated treatment efficacy.

20. A method of assessing the efficacy of treatment of a neurological disorder comprising the steps of:

acquiring electrophysiological signals from a body suffering from a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, said signals being acquired through electrodes placed on the body, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

calculating from said electrophysiological signals at least one feature relating to the efficacy of said treatment without referencing said at least one feature to a normative data set, said feature being a measure of a self-reported mood or anxiety score.

21. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said treatment is neurostimulation.

22. The method of assessing the efficacy of treatment of a neurological disorder of claim 21 wherein said neurostimulation is deep brain stimulation.

23. The method of assessing the efficacy of treatment of a neurological disorder of claim 21 wherein said neurostimulation is vagus nerve stimulation.

24. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said treatment is the administration of a pharmacological agent.

25. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said treatment is electroconvulsive therapy.

26. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said treatment is transcranial magnetic stimulation.

27. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 further comprising the step of combining said features into an index.

28. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said at least one feature is calculated from a spectral array.

29. The method of assessing the efficacy of treatment of a neurological disorder of claim 27 wherein said at least one feature is calculated from a power spectral array.

30. The method of assessing the efficacy of treatment of a neurological disorder of claim 27 wherein said at least one feature is calculated from a bispectral array.

31. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said at least one feature is a time domain feature.

32. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said at least two electrodes are placed in a bilateral montage.

33. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said at least two electrodes are placed in an unilateral montage.

34. The method of assessing the efficacy of treatment of a neurological disorder of claim 20 wherein said feature is the interhemispheric difference in a metric calculated from each electrophysiological signal.

35. The method of assessing the efficacy of treatment of a neurological disorder of claim 34 wherein said metric is a spectral feature.

36. The method of assessing the efficacy of treatment of a neurological disorder of claim 34 wherein said metric is a time domain feature.

37. A method of assessing the efficacy of treatment of a neurological disorder comprising:

positioning a least two electrodes on a body being treated for a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

acquiring a first electrophysiological signal from the body at a baseline condition;

acquiring a second electrophysiological signal from the body during a subsequent condition;

calculating at least one feature relating to the patient state during the baseline condition without referencing said at least one feature relating to the patient state during the baseline condition to a normative data set, said at least one feature relating to the patient state during the baseline condition being a measure of a self-reported mood or anxiety score;

calculating at least one feature relating to the patient state during the subsequent condition without referencing said at least one feature relating to the patient state during the subsequent condition to a normative data set, said at least one feature relating to the patient state during the subsequent condition being a measure of a self-reported mood or anxiety score;

calculating at the difference between the features calculated during the baseline and subsequent conditions, such that the difference relates to the efficacy of said treatment.

38. A method of optimizing the efficacy of treatment of a neurological disorder comprising:

positioning at least two electrodes on a body being treated for a neurological disorder which is one or more of depression, major depressive disorder, obsessive compulsive disorder, dementia, mood disorders and anxiety disorders, wherein one of said at least two electrodes for acquiring electrophysiological signals from the body is positioned at electrode position Fp z ;

acquiring electrophysiological signals from the body;

calculating at least one feature relating to the efficacy of said treatment without referencing said at least one feature to a normative data set, said at least one feature being a measure of a self-reported mood or anxiety score;

varying treatment parameters in order to maximize the calculated treatment efficacy.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2012
From: NELLCOR PURITAN BENNETT LLC
To: COVIDIEN LP
Reel/Frame 029431/0511 →
MERGER Recorded Jan 11, 2010
From: ASPECT MEDICAL SYSTEMS, INC.
To: ASPECT MEDICAL SYSTEMS, LLC
Reel/Frame 023758/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2010
From: ASPECT MEDICAL SYSTEMS, LLC
To: NELLCOR PURITAN BENNETT LLC
Reel/Frame 023758/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2004
From: DEVLIN, PHILIP H.; GREENWALD, SCOTT D.
To: ASPECT MEDICAL SYSTEMS, INC.
Reel/Frame 015333/0305 →
Continuity (3)
Provisional Application 6046835000 · May 6, 2003
Provisional Application 6053424700 · Jan 5, 2004
Related Publication 20050043774A1 · Feb 24, 2005